CN105440076A - Method for preparing tenofovir disoproxil fumarate - Google Patents
Method for preparing tenofovir disoproxil fumarate Download PDFInfo
- Publication number
- CN105440076A CN105440076A CN201511013861.4A CN201511013861A CN105440076A CN 105440076 A CN105440076 A CN 105440076A CN 201511013861 A CN201511013861 A CN 201511013861A CN 105440076 A CN105440076 A CN 105440076A
- Authority
- CN
- China
- Prior art keywords
- tenofovir disoproxil
- disoproxil fumarate
- method preparing
- tynofovir
- preparing tenofovir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Abstract
The invention provides a method for preparing tenofovir disoproxil fumarate, and belongs to the technical field of organic compound synthesis. According to the method, tenofovir is taken as a starting material, and tenofovir disoproxil fumarate is obtained through esterification, salt formation and refining. The method provided by the invention is mild in reaction condition, low in production cost, and high in product yield and quality, and facilitates industrialized production.
Description
Technical field
The invention belongs to organic compound synthesis technical field, particularly, relate to a kind of method preparing tenofovir disoproxil fumarate.
Background technology
A kind of novel nucleoside acids of tenofovir disoproxil fumarate reverse transcriptase inhibitors.Suppress reversed transcriptive enzyme with the method similar with efabirenz, thus there is potential Anti-HIV-1 Active.The activeconstituents tynofovir Diphosphonate of tynofovir combines with natural ribodesose substrate by direct competitive and suppresses varial polymerases, and by inserting terminating chain in people DNA.Tynofovir, hardly through gastrointestinal absorption, therefore carries out esterification, salify, becomes tenofovir disoproxil fumarate.Tenofovir disoproxil has water-soluble, can be rapidly absorbed and be degraded into active substance tynofovir, and then tynofovir changes active metabolite tynofovir Diphosphonate again into.Tenofovir disoproxil has the effect suppressing hepatitis B virus duplication and the stable state of an illness, and to a certain degree can reduce transaminase, can play liver-protective effect, have reasonable effect to the treatment of hepatitis B.Although although the ratio that current China patients infected hiv accounts for total population is very low, number of the infected has occupied the 2nd in Asia, and has rising tendency year by year, so the demand of AIDS medicine can increase gradually.Tenofovir disoproxil fumarate is as the free AIDS antiretroviral therapy first-line drug of country, and demand can obviously increase.So to the improvement of tenofovir disoproxil fumarate synthesis technique and optimize to society and enterprise self all significant.
The existing production technique of tenofovir disoproxil fumarate after esterification, synthesizes tenofovir disoproxil as starting raw material and chloromethyl propylene carbonate from tynofovir monohydrate or anhydride, then tenofovir disoproxil fumarate is obtained with fumaric acid salify, but reaction conversion ratio is on the low side in existing synthetic technology, its major cause is because tynofovir first carries out mono-esterification when esterification, then continue to be reacted into dibasic acid esters, but because steric hindrance increases after mono-esterification, reactive behavior reduces, double esterification difficulty strengthens, and cause has monoesters exist and affect reaction yield always in reaction.And because mono-substituted products exists in a large number, post-reaction treatment is also more difficult, and quality product is comparatively difficult to ensure card.Although promote that the forward reacted carries out by increasing raw material charging capacity, this can improve production cost greatly, and when raw material is increased to a certain amount of, reaction forward carries out reaching a balance, does not transform in continuation.In addition, in existing synthetic technology, esterification all uses high boiling solvent, and tenofovir disoproxil is at high temperature unstable, cannot directly reclaim, so generally all adopt a large amount of frozen water to carry out saltouing or a large amount of water washings during aftertreatment, cause a large amount of solvent to enter Sewage treatment systems, not only increase the pressure of environmental protection, and cannot recycle due to solvent and cause product cost too high.
Summary of the invention
Goal of the invention: for the deficiencies in the prior art, the invention provides a kind of method preparing tenofovir disoproxil fumarate, and reaction conditions is gentle, and production cost is low, and product yield is high, quality good, is convenient to the advantages such as suitability for industrialized production.
Technical scheme: the invention provides a kind of method preparing tenofovir disoproxil fumarate, comprise the following steps:
(1) tynofovir, ethanol and N-Methyl pyrrolidone mixed solvent are joined reaction unit, control temperature, at 20-25 DEG C, successively drips acid binding agent and chloromethyl propylene carbonate under agitation condition;
(2) 55-60 DEG C of insulation reaction 6-10 hour is warming up to;
(3) step (2) reaction solution is evaporated to below 40 DEG C absence of liquid to flow out;
(4) in concentrated raffinate, extraction liquid is added, layering extraction after stirring;
(5) step (4) gained organic phase purified water washing 2-3 time; Be evaporated to dry more after drying;
(6) in the concentrated raffinate of step (5), add solvent, be stirred under 45-55 DEG C of condition and dissolve completely;
(7) in step (6) reaction solution, add fumaric acid, be cooled to 10-15 DEG C of insulated and stirred crystallization 2-6 hour;
(8) filter; Extremely dry through 40-45 DEG C of vacuum-drying after filter cake solvent wash, obtain described tenofovir disoproxil fumarate.
The method preparing tenofovir disoproxil fumarate of the present invention, method is succinct, reaction conditions is gentle, wherein the mol ratio of tynofovir, chloromethyl propylene carbonate, fumaric acid and acid binding agent is about 1:0.5:1:0.5, production cost is low, and it is high to react overall yield, and quality product is also relatively stable.In addition, make mixed solvent with ethanol and N-Methyl pyrrolidone and carry out esterification, use lower boiling ethanol as primary solvent, can by recycled solvent under the condition that temperature is lower, under the prerequisite not affecting quality product, solve the high expensive problem because solvent loss causes, also mitigate the pressure of environmental protection.
Further, the above-mentioned method preparing tenofovir disoproxil fumarate, described tynofovir is tynofovir monohydrate or tynofovir anhydride.Raw material is easy to get, and application cost is low.
Further, the above-mentioned method preparing tenofovir disoproxil fumarate, described acid binding agent is triethylamine.Triethylamine, as acid binding agent, promotes that reaction is carried out, and effective.
Further, the above-mentioned method preparing tenofovir disoproxil fumarate, the volume ratio of described N-Methyl pyrrolidone and ethanol is 1:8-10.Ratio is reasonable, uses lower boiling ethanol as primary solvent.
Further, the above-mentioned method preparing tenofovir disoproxil fumarate, described step (4) described extraction liquid is the mixing solutions of ethyl acetate and sodium bicarbonate.Raw material sources are wide, and application cost is low.
Preferred as one of the present invention, the above-mentioned method preparing tenofovir disoproxil fumarate, the volume ratio of described sodium bicarbonate and ethyl acetate is 1:1.25-2.5.Ratio is reasonable.
Further, the above-mentioned method preparing tenofovir disoproxil fumarate, described sodium bicarbonate is 6% sodium hydrogen carbonate solution.Application cost is low.
Further, the above-mentioned method preparing tenofovir disoproxil fumarate, described step (5) uses anhydrous sodium sulfate drying.Raw material sources are wide, and application cost is low.
Further, the above-mentioned method preparing tenofovir disoproxil fumarate, described step (6) and the middle solvent of step (8) are Virahol.Virahol, as solvent, makes follow-up salting-out condition gentle.And only use a small amount of washed with isopropyl alcohol, three-protection design burden is little, reaches the requirement of cleaner production, is conducive to suitability for industrialized production.
Beneficial effect: compared with prior art, the present invention has the following advantages: the method preparing tenofovir disoproxil fumarate of the present invention, and method is succinct, raw material sources are wide, and reaction conditions is gentle, and production cost is low, and it is high to react overall yield, and quality product is also relatively stable.In addition, make mixed solvent with ethanol and N-Methyl pyrrolidone and carry out esterification, use lower boiling ethanol as primary solvent, can by recycled solvent under the condition that temperature is lower, under the prerequisite not affecting quality product, solve the high expensive problem because solvent loss causes, also mitigate the pressure of environmental protection.
Accompanying drawing explanation
Fig. 1 is the synthetic route chart of tenofovir disoproxil fumarate of the present invention.
Embodiment
By several specific embodiment, will illustrate the present invention further below, these embodiments, just in order to describe the problem, are not a kind of restriction.
Embodiment 1
As shown in Figure 1, tenofovir disoproxil fumarate synthesis technique is totally 2 step reactions, is starting raw material by tynofovir, through esterification, becomes salt refining to obtain tenofovir disoproxil fumarate.
1. esterification:
400ml ethanol is added in 1000ml reaction flask, the N-Methyl pyrrolidone of 50ml and 40g tynofovir monohydrate, open and stir, control temperature drips 67g triethylamine at 20 DEG C, drip off and continue to drip 100g chloromethyl propylene carbonate, reaction system is warming up to 57 DEG C of insulation reaction 8 hours after dripping off, in detection reaction, monoesters is less than 10%, reaction solution is evaporated to below 40 DEG C absence of liquid to flow out, 500ml ethyl acetate is added in concentrated raffinate, the sodium hydrogen carbonate solution of 200ml6%, layering extraction after stirring, organic phase continuation 200ml purified water washes twice, gained organic phase is evaporated to dry after anhydrous sodium sulfate drying, gained concentrates raffinate and is directly used in the next step.
2. salify
Upwards add 200ml Virahol in the concentrated raffinate of step, 50 DEG C are heated under stirring, in question response bottle molten clear after, add 15g fumaric acid, add and reaction solution is cooled to 10 DEG C of insulated and stirred crystallizatioies 4 hours, filter, filter cake to obtain 69g tenofovir disoproxil fumarate finished product with extremely doing through 40 DEG C of vacuum-dryings after a small amount of washed with isopropyl alcohol.Total recovery 83%, purity 99.4%.
Embodiment 2
As shown in Figure 1, tenofovir disoproxil fumarate synthesis technique is totally 2 step reactions, is starting raw material by tynofovir, through esterification, becomes salt refining to obtain tenofovir disoproxil fumarate.
1. esterification:
900ml ethanol is added in 2000ml reaction flask, the N-Methyl pyrrolidone of 100ml and 100g tynofovir anhydride, open and stir, control temperature drips 168g triethylamine at 25 DEG C, drip off and continue to drip 250g chloromethyl propylene carbonate, reaction system is warming up to 60 DEG C of insulation reaction 10 hours after dripping off, in detection reaction, monoesters is less than 10%, reaction solution is evaporated to below 40 DEG C absence of liquid to flow out, 500ml ethyl acetate is added in concentrated raffinate, the sodium hydrogen carbonate solution of 400ml6%, layering extraction after stirring, organic phase continuation 400ml purified water washs three times, gained organic phase is evaporated to dry after anhydrous sodium sulfate drying, gained concentrates raffinate and is directly used in the next step.
2. salify
Upwards add 500ml Virahol in the concentrated raffinate of step, 55 DEG C are heated under stirring, in question response bottle molten clear after, add 38g fumaric acid, add and reaction solution is cooled to 15 DEG C of insulated and stirred crystallizatioies 2 hours, filter, filter cake to obtain 166g tenofovir disoproxil fumarate finished product with extremely doing through 45 DEG C of vacuum-dryings after a small amount of washed with isopropyl alcohol.Total recovery 80%, purity 99.2%.
Embodiment 3
As shown in Figure 1, tenofovir disoproxil fumarate synthesis technique is totally 2 step reactions, is starting raw material by tynofovir, through esterification, becomes salt refining to obtain tenofovir disoproxil fumarate.
1. esterification:
400ml ethanol is added in 1000ml reaction flask, the N-Methyl pyrrolidone of 40ml and 40g tynofovir monohydrate, open and stir, control temperature drips 67g triethylamine at 22 DEG C, drip off and continue to drip 100g chloromethyl propylene carbonate, reaction system is warming up to 55 DEG C of insulation reaction 6 hours after dripping off, in detection reaction, monoesters is less than 10%, reaction solution is evaporated to below 40 DEG C absence of liquid to flow out, 500ml ethyl acetate is added in concentrated raffinate, the sodium hydrogen carbonate solution of 250ml6%, layering extraction after stirring, organic phase continuation 200ml purified water washes twice, gained organic phase is evaporated to dry after anhydrous sodium sulfate drying, gained concentrates raffinate and is directly used in the next step.
2. salify
Upwards add 200ml Virahol in the concentrated raffinate of step, 45 DEG C are heated under stirring, in question response bottle molten clear after, add 15g fumaric acid, add and reaction solution is cooled to 12 DEG C of insulated and stirred crystallizatioies 6 hours, filter, filter cake to obtain 67g tenofovir disoproxil finished product with extremely doing through 42 DEG C of vacuum-dryings after a small amount of washed with isopropyl alcohol.Total recovery 81%, purity 99.1%.
To sum up, use ethanol and N-Methyl pyrrolidone to make mixed solvent and carry out esterification in the present invention, can control below 10% by the residual of monoesters in reaction, reaction conversion ratio promotes greatly, and total recovery brings up to more than 80%.
The above is only several embodiments of invention, and it should be pointed out that for those skilled in the art, under the prerequisite not departing from inventive principle, can also make some improvement, these improvement also should be considered as protection scope of the present invention.
Claims (9)
1. prepare a method for tenofovir disoproxil fumarate, it is characterized in that: comprise the following steps:
(1) tynofovir, ethanol and N-Methyl pyrrolidone mixed solvent are joined reaction unit, control temperature, at 20-25 DEG C, successively drips acid binding agent and chloromethyl propylene carbonate under agitation condition;
(2) 55-60 DEG C of insulation reaction 6-10 hour is warming up to;
(3) step (2) reaction solution is evaporated to below 40 DEG C absence of liquid to flow out;
(4) in concentrated raffinate, extraction liquid is added, layering extraction after stirring;
(5) step (4) gained organic phase purified water washing 2-3 time; Be evaporated to dry more after drying;
(6) in the concentrated raffinate of step (5), add solvent, be stirred under 45-55 DEG C of condition and dissolve completely;
(7) in step (6) reaction solution, add fumaric acid, be cooled to 10-15 DEG C of insulated and stirred crystallization 2-6 hour;
(8) filter; Extremely dry through 40-45 DEG C of vacuum-drying after filter cake solvent wash, obtain described tenofovir disoproxil fumarate.
2. the method preparing tenofovir disoproxil fumarate according to claim 1, is characterized in that: described tynofovir is tynofovir monohydrate or tynofovir anhydride.
3. the method preparing tenofovir disoproxil fumarate according to claim 1, is characterized in that: described acid binding agent is triethylamine.
4. the method preparing tenofovir disoproxil fumarate according to claim 1, is characterized in that: the volume ratio of described N-Methyl pyrrolidone and ethanol is 1:8-10.
5. the method preparing tenofovir disoproxil fumarate according to claim 1, is characterized in that: described step (4) described extraction liquid is the mixing solutions of ethyl acetate and sodium bicarbonate.
6. the method preparing tenofovir disoproxil fumarate according to claim 5, is characterized in that: the volume ratio of described sodium bicarbonate and ethyl acetate is 1:1.25-2.5.
7. the method preparing tenofovir disoproxil fumarate according to claim 5 or 6, is characterized in that: described sodium bicarbonate is 6% sodium hydrogen carbonate solution.
8. the method preparing tenofovir disoproxil fumarate according to claim 1, is characterized in that: described step (5) uses anhydrous sodium sulfate drying.
9. the method preparing tenofovir disoproxil fumarate according to claim 1, is characterized in that: described step (6) and the middle solvent of step (8) are Virahol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511013861.4A CN105440076A (en) | 2015-12-31 | 2015-12-31 | Method for preparing tenofovir disoproxil fumarate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511013861.4A CN105440076A (en) | 2015-12-31 | 2015-12-31 | Method for preparing tenofovir disoproxil fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105440076A true CN105440076A (en) | 2016-03-30 |
Family
ID=55550767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511013861.4A Pending CN105440076A (en) | 2015-12-31 | 2015-12-31 | Method for preparing tenofovir disoproxil fumarate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105440076A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107400145A (en) * | 2017-08-03 | 2017-11-28 | 江苏汉斯通药业有限公司 | The synthetic method of high-purity tenofovir disoproxil fumarate |
| CN108794531A (en) * | 2018-04-04 | 2018-11-13 | 盐城迪赛诺制药有限公司 | A kind of preparation method of high-purity tenofovir disoproxil fumarate |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130165413A1 (en) * | 2010-12-13 | 2013-06-27 | Aptuit Laurus Private Limited | Process for the preparation of tenofovir |
| CN103360425A (en) * | 2012-04-01 | 2013-10-23 | 安徽贝克联合制药有限公司 | Synthesis method of tenofovir disoproxil and fumarate thereof |
| CN103374038A (en) * | 2012-04-11 | 2013-10-30 | 广州白云山制药股份有限公司广州白云山制药总厂 | Preparation method of antiviral medicine |
| WO2014033688A1 (en) * | 2012-09-03 | 2014-03-06 | Ithemba Pharmaceuticals (Proprietary) Limited | A process for the preparation of (r)-9-[2-(phosphonometh-oxy)propyl]adenine (pmpa) |
| WO2014141092A2 (en) * | 2013-03-12 | 2014-09-18 | Shasun Pharmaceuticals Limited | Improved process for the preparation of tenofovir |
| CN104230992A (en) * | 2014-08-27 | 2014-12-24 | 太仓运通生物化工有限公司 | Preparation method of high-purity fumaric acid tenofovir disoproxil fumarate |
| CN104610360A (en) * | 2015-02-13 | 2015-05-13 | 山东新时代药业有限公司 | Method for preparing tenofovir disoproxil fumarate |
| CN106008603A (en) * | 2016-06-03 | 2016-10-12 | 东北制药集团股份有限公司 | Preparation methods of tenofovir disoproxil and fumarate thereof |
-
2015
- 2015-12-31 CN CN201511013861.4A patent/CN105440076A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130165413A1 (en) * | 2010-12-13 | 2013-06-27 | Aptuit Laurus Private Limited | Process for the preparation of tenofovir |
| CN103360425A (en) * | 2012-04-01 | 2013-10-23 | 安徽贝克联合制药有限公司 | Synthesis method of tenofovir disoproxil and fumarate thereof |
| CN103374038A (en) * | 2012-04-11 | 2013-10-30 | 广州白云山制药股份有限公司广州白云山制药总厂 | Preparation method of antiviral medicine |
| WO2014033688A1 (en) * | 2012-09-03 | 2014-03-06 | Ithemba Pharmaceuticals (Proprietary) Limited | A process for the preparation of (r)-9-[2-(phosphonometh-oxy)propyl]adenine (pmpa) |
| WO2014141092A2 (en) * | 2013-03-12 | 2014-09-18 | Shasun Pharmaceuticals Limited | Improved process for the preparation of tenofovir |
| CN104230992A (en) * | 2014-08-27 | 2014-12-24 | 太仓运通生物化工有限公司 | Preparation method of high-purity fumaric acid tenofovir disoproxil fumarate |
| CN104610360A (en) * | 2015-02-13 | 2015-05-13 | 山东新时代药业有限公司 | Method for preparing tenofovir disoproxil fumarate |
| CN106008603A (en) * | 2016-06-03 | 2016-10-12 | 东北制药集团股份有限公司 | Preparation methods of tenofovir disoproxil and fumarate thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107400145A (en) * | 2017-08-03 | 2017-11-28 | 江苏汉斯通药业有限公司 | The synthetic method of high-purity tenofovir disoproxil fumarate |
| CN108794531A (en) * | 2018-04-04 | 2018-11-13 | 盐城迪赛诺制药有限公司 | A kind of preparation method of high-purity tenofovir disoproxil fumarate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6177434B2 (en) | Aqueous phase synthesis of nano-lithium iron phosphate at normal pressure and without crystal water | |
| CN105418684A (en) | New method for synthesizing tenofovir disoproxil fumarate | |
| CN104086379A (en) | Method for synthesizing forxiga intermediate | |
| CN102070483A (en) | Method for preparing lidocaine | |
| CN104974073A (en) | Preparation method of silodosin intermediate | |
| CN103570609A (en) | Preparation method for 2,3-dichloropyridine | |
| CN104744249A (en) | Method for preparing stable salt of aspirin and alkaline amino acid | |
| CN109956976A (en) | A kind of preparation method of the double oxalic acid lithium phosphates of difluoro | |
| CN105440076A (en) | Method for preparing tenofovir disoproxil fumarate | |
| CN108659025A (en) | The preparation method of gram vertical boron sieve | |
| CN101486753A (en) | Novel method for synthesizing finasteroid | |
| CN1982297A (en) | Synthesis of pyridine-N-oxide | |
| CN105440078A (en) | Method for synthesizing tenofovir disoproxil fumarate conveniently | |
| CN105418682A (en) | Method for preparing tenofovir disoproxil fumarate through two-step method | |
| CN105418683A (en) | Preparation method for tenofovir disoproxil fumarate | |
| CN102381970A (en) | Method for preparing flurbiprofen axetil compound | |
| CN105218544A (en) | A kind of synthetic method of Eliquis intermediate | |
| CN104098462B (en) | The method for splitting of the diphenyl-propionic acid racemoid of 2 hydroxyl, 3 methoxyl group 3,3 | |
| CN105481898A (en) | Method for synthesizing tenofovir fumarate by two-step process | |
| CN105440077A (en) | Method for synthesizing tenofovir disoproxil fumarate | |
| CN105481897A (en) | New method for preparing tenofovir disoproxil fumarate | |
| CN105566393A (en) | Synthetic method of tenofovir disoproxil fumarate | |
| CN104072369B (en) | A kind of technique preparing Diisopropyl malonate | |
| CN106349121B (en) | The preparation method of one kind 3,5- dichlorobenzoyl chlorides | |
| CN105503628B (en) | A kind of preparation method of D asparatates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160330 |
|
| RJ01 | Rejection of invention patent application after publication |